Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP)

Today's Latest Price: $78.72 USD

0.19 (-0.24%)

Updated Jan 15 4:00pm

Add HZNP to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

HZNP Stock Summary

  • The price/operating cash flow metric for Horizon Therapeutics Public Ltd Co is higher than 90.83% of stocks in our set with a positive cash flow.
  • Over the past twelve months, HZNP has reported earnings growth of 219.63%, putting it ahead of 93.49% of US stocks in our set.
  • Revenue growth over the past 12 months for Horizon Therapeutics Public Ltd Co comes in at 40.76%, a number that bests 87.84% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Horizon Therapeutics Public Ltd Co, a group of peers worth examining would be TECH, AKAM, WST, MASI, and FTNT.
  • HZNP's SEC filings can be seen here. And to visit Horizon Therapeutics Public Ltd Co's official web site, go to www.horizontherapeutics.com.

HZNP Stock Price Chart Interactive Chart >

Price chart for HZNP

HZNP Price/Volume Stats

Current price $78.72 52-week high $86.67
Prev. close $78.91 52-week low $23.81
Day low $76.80 Volume 1,414,500
Day high $79.32 Avg. volume 1,622,160
50-day MA $72.91 Dividend yield N/A
200-day MA $62.99 Market Cap 17.37B

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio

Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.

HZNP Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$78.72$19.9 -75%

We started the process of determining a valid price forecast for Horizon Therapeutics Public Ltd Co with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 22th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 74.67%. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:

  • The company's balance sheet shows it gets 95% of its capital from equity, and 5% of its capital from debt. Notably, its equity weight is greater than 68.63% of US equities in the Healthcare sector yielding a positive free cash flow.
  • The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than only 17.7% of the free cash flow producing stocks we're observing.
  • Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 189 -- greater than 98.86% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Horizon Therapeutics Public Ltd Co? See CNC, IDXX, MDT, BSX, and EHC.

HZNP Latest News Stream

Event/Time News Detail
Loading, please wait...

HZNP Latest Social Stream

Loading social stream, please wait...

View Full HZNP Social Stream

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New KRYSTEXXA® (pegloticase injection) Trials

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials. “Amid the most challenging environment we have ever faced, we had a record year of performance, exceeding our full-year 2020 net sales and adjusted EBITDA guidance, driven by the significant outperformance of TEPEZZA and the strong second-half performance of KRYSTEXXA,” said Tim Walbert, chairman, president and chief executive officer,

Business Wire | January 11, 2021

The Horizon Therapeutics (NASDAQ:HZNP) Share Price Has Soared 428%, Delighting Many Shareholders

Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. Mistakes are...

Yahoo | January 8, 2021

Selecta: ImmTOR Platform's Potential In Key

Selecta Biosciences (SELB) value proposition is straightforward: many drugs produce an immune response that limits their efficacy while enhancing their adverse events profile. That means, you have a disease, and you take a drug to treat that disease, however, your body thinks of that drug as an enemy, and tries...

Avisol Capital Partners on Seeking Alpha | December 25, 2020

Top Healthcare Stocks for January 2021

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Yahoo | December 22, 2020

Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare Conference

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 39th Annual J.P. Morgan Healthcare Conference. Tim Walbert, chairman, president and chief executive officer, will present at 11:40 a.m. ET on Jan. 12, 2021.

Yahoo | December 22, 2020

Read More 'HZNP' Stories Here

HZNP Price Returns

1-mo 12.97%
3-mo 0.33%
6-mo 35.12%
1-year 105.00%
3-year 417.55%
5-year 344.24%
YTD 7.61%
2020 102.07%
2019 85.26%
2018 33.84%
2017 -9.77%
2016 -25.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8852 seconds.